Myfortic — Mycophenolic acid 180 mg, 120 pcs, Novartis

Myfortic 180 mg — Mycophenolic Acid 180 mg Tablets, 120 Tabs

Product code: 488

5900₴ 6400₴ -8% On order · from 14 days
1
Active ingredient
Dosage form Film-coated tablets
Tablets per pack 120
Packaging Blisters in a box

Myfortic is a selective immunosuppressive medicinal product supplied as gastro-resistant tablets, indicated for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal transplants. The active pharmaceutical ingredient is mycophenolic acid in the form of sodium mycophenolate at a strength of 180 mg (Mycophenolic acid gastro-resistant tablets 180 mg). The product is developed and manufactured by the global pharmaceutical corporation Novartis.

Myfortic is engineered as an advanced alternative to conventional mycophenolate mofetil. Its principal technological feature is a specialized enteric coating (gastro-resistant matrix) that shields the gastric mucosa from direct irritant effects and prevents active substance release in the stomach. Mycophenolic acid release occurs within the alkaline environment of the small intestine, significantly reducing the frequency and severity of upper gastrointestinal adverse effects (such as nausea and abdominal pain) and improving overall patient tolerability.

Supplied in an outer carton containing 120 tablets (12 blister strips of 10 tablets each). Intended exclusively for prescription use by a transplant specialist in combination regimens with cyclosporine and corticosteroids.

Key Clinical Features and Advantages of Myfortic 180 mg:

  • ✅ Gastric Mucosa Protection: Enteric coating minimizes dyspeptic symptoms and upper gastrointestinal irritation.
  • ✅ Selective Action: Selectively inhibits T- and B-lymphocyte proliferation, suppressing cell-mediated allograft responses.
  • ✅ Reliable Rejection Prophylaxis: High clinical efficacy in triple immunosuppressive regimens (combined with cyclosporine and steroids).
  • ✅ Original Novartis Quality: Rigorous Swiss manufacturing standards ensuring chemical purity and dosing consistency.
  • ✅ Convenient 180 mg Strength: Enables precise individual patient dose titration.

Myfortic 180 mg is supplied as gastro-resistant coated tablets.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Mycophenolic acid (as sodium mycophenolate) — 180 mg (equivalent to 192.4 mg sodium mycophenolate).
  • Excipients (Core): Maize starch, crospovidone, povidone (K-30), colloidal anhydrous silica, magnesium stearate. Coating: hypromellose phthalate, titanium dioxide (E171), iron oxide yellow (E172), indigo carmine aluminium lake (E132).

Packaging and Presentation: Round, biconvex, light green enteric-coated tablets debossed with "C" on one side. 10 tablets per blister strip. 12 blister strips (total 120 tablets) are packaged in an outer carton displaying Myfortic 180 mg along with Novartis corporate graphics and prescribing information.

Pharmacodynamics:
Mycophenolic acid (MPA) is a potent, selective, non-competitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in the de novo pathway of guanosine nucleotide synthesis. Because T- and B-lymphocyte proliferation is critically dependent on de novo purine synthesis while other cell types utilize salvage pathways, MPA exerts cytostatic effects preferentially on lymphocytes, effectively preventing the immune response leading to graft rejection.

Pharmacokinetics:

  • Absorption: Following oral administration, sodium mycophenolate is rapidly and completely absorbed. Due to enteric coating, peak MPA plasma concentrations (Tmax) are reached approximately 1.5 to 2.0 hours post-dose. Absolute bioavailability is approximately 72%.
  • Distribution: Plasma protein binding of MPA is approximately 97%. Steady-state volume of distribution is 50 liters.
  • Metabolism: MPA is metabolized primarily via glucuronyl transferase to form the pharmacologically inactive phenolic glucuronide of mycophenolic acid (MPAG).
  • Elimination: Excreted predominantly renally as MPAG (approximately 93% of the dose), with fecal elimination via bile contributing remainder. Terminal elimination half-life (T1/2) averages 12 hours.

Myfortic is indicated in adult patients for:

  • Transplant Rejection Prophylaxis: Indicated in combination with cyclosporine microemulsion and corticosteroids for the prophylaxis of acute renal transplant rejection in adult allogeneic kidney transplant recipients.

Myfortic is administered orally twice daily (morning and evening). Tablets must be swallowed whole with a glass of water; they must not be broken, crushed, or chewed, as doing so compromises the enteric-coated barrier.

Dosing Regimen:
The recommended dose for renal transplant patients is 720 mg (four 180 mg tablets or two 360 mg tablets) twice daily (total daily dose of 1440 mg). Therapy should be initiated within 24 hours following kidney transplantation.

Special Notes: Myfortic may be taken with or without food (although fasting may accelerate absorption). Dose adjustments are generally unnecessary in elderly patients or those with mild renal impairment.

Administration of Myfortic is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to sodium mycophenolate, mycophenolic acid, mycophenolate mofetil, or any excipient.
  • Pregnancy: Contraindicated in pregnant women (high risk of spontaneous abortion and congenital malformations) and women of childbearing potential not utilizing effective contraception.
  • Lactation: Breastfeeding is strictly prohibited during treatment.

Evaluated drug interactions with Myfortic include:

  • Antacids and Proton Pump Inhibitors (aluminium/magnesium hydroxide, pantoprazole): Co-administration of antacids may reduce MPA systemic bioavailability. Simultaneous dosing should be avoided.
  • Acyclovir and Ganciclovir: Concentrations of these antivirals and MPAG may increase during co-administration, particularly in renally impaired patients.
  • Tacrolimus: When converting patients from cyclosporine to tacrolimus or vice versa, changes in MPA pharmacokinetics must be considered.
  • Cholestyramine and Bile Acid Sequestrants: Interrupt enterohepatic recirculation of MPA, significantly lowering blood concentrations. Co-administration is not recommended.

Pregnancy:
Myfortic is contraindicated during pregnancy. The drug possesses proven teratogenic potential (increasing miscarriage rates and congenital malformations of the ear, face, and heart). Women of childbearing potential must utilize at least two reliable forms of effective contraception prior to, during, and for 6 weeks following therapy cessation.

Lactation:
Mycophenolic acid is excreted into human breast milk. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Gastrointestinal Tract: Diarrhea, nausea, vomiting, abdominal pain, constipation, dyspepsia, gastritis, esophagitis (enteric coating reduces gastritis incidence compared to mycophenolate mofetil, but gastrointestinal disturbances remain).
  • Hematologic Toxicity: Leukopenia, anemia, thrombocytopenia, lymphopenia. Regular complete blood counts are mandatory.
  • Infections: Heightened risk of opportunistic, viral (cytomegalovirus), bacterial, and fungal infections.
  • Nervous System: Headache, insomnia, tremor, dizziness.
  • General Disorders: Fatigue, peripheral edema, pyrexia, asthenia.

Symptoms:
Clinical experience with sodium mycophenolate overdose is limited. Anticipated symptoms include exaggerated adverse reactions: severe myelosuppression and pronounced gastrointestinal disturbances (nausea, vomiting, diarrhea).

Treatment:
No specific antidote exists. Supportive and symptomatic care should be initiated. Due to high plasma protein binding, hemodialysis is ineffective for removing active MPA.

Storage Requirements for Myfortic 180 mg:

    🌡️ Temperature Range: Store in original packaging protected from moisture at temperatures not exceeding 30 °C. 👶 Safety Precautions: Keep out of reach of children. ⏳ Shelf Life: Stated on outer carton and blister foil. Do not use past expiration date. Prescription-only medicine.

To verify authenticity of genuine Myfortic 180 mg manufactured by Novartis, inspect the following features:

  • ✅ Corporate Logo: Distinctive Novartis corporate logo printed on the outer carton and blister foil.
  • ✅ Packaging Markings: Laser-printed Batch No., manufacturing date, and expiration date matching carton and blisters, displaying Myfortic 180 mg.
  • ✅ Tablet Appearance: Gastro-resistant tablets feature a distinct light green color, round biconvex shape, and "C" debossing on one side.
  • ✅ Prescribing Information: Includes an official official leaflet inside the outer carton.
On order · from 14 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 07.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00